Incidence and significance of the JAK2 V617F mutation in patients with chronic myeloproliferative disorders
- 82 Downloads
The chronic myeloproliferative disorders (MPD) are clonal haemopoietic stem cell disorders.
The incidence of JAK2 V617F mutation was sought in a population of patients with MPD.
The JAK2 V617 mutation status was determined in 79 patients with known MPD and 59 patients with features suggestive of MPD.
The mutation was found in patients with polycythaemia vera, essential thrombocythaemia, idiopathic myelofibrosis and in patients with other chronic myeloproliferative disorders. Eight JAK2 V617F positive cases were identified amongst those patients with features suggestive of MPD.
The incidence of the JAK2 V617F mutation in MPD patients is similar to that reported by other groups. The assay confirmed and refined the diagnosis of several patients with features indicative of MPD. We suggest screening for this mutation in all patients with known and suspected MPD as identification is valuable in classification and is a potential target for signal transduction therapy.
KeywordsEssential thrombocythaemia Idiopathic myelofibrosis JAK2 V617F Myeloproliferative disorders Polycythaemia vera Tyrosine kinase
The authors are grateful to Professor S. McCann, Dr P. Browne and Dr E. Vandenberghe, Department of Haematology, St. James’s Hospital, Dublin and all other clinicians who have provided patient material for molecular investigation of MPD.
- 1.Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World health organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, LyonGoogle Scholar
- 19.McLornan DP, Percy MJ, Jones AV, Cross NC, McMullin MF (2005) Chronic neutrophilic leukaemia with an associated V617F JAK2 tyrosine kinase mutation. Haematologica 90:1696–1697Google Scholar
- 23.van Dongen JJ, Macintyre EA, Gabert JA et al (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Report of the BIOMED-1 concerted action: investigation of minimal residual disease in acute leukaemia. Leukemia 13:1901–1928PubMedCrossRefGoogle Scholar
- 24.Campbell PJ, Green AR (2005) Management of polycythemia vera and essential thrombocythemia. Hematology (Am Soc Hematol Educ Program), pp 201–208Google Scholar